BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:With Nintedanib and Pirfenidone set to lose their patents in t
 he next 3-6 years\, Pliant Therapeutics moving into phase 2b\, readouts e
 xpected from FibroGen's phase 3 trial and Galecto's phase 2 study and Bri
 stol Myers Squibb's and Boehringer Ingelheim's clinical trials both well 
 under way...the race is on to advance the next generation of IPF drugs an
 d beat the benchmark set by the standard of care.\n\nWe're at the precipi
 ce of hailing disease-modifying IPF drugs to patients with the increasing
  understanding of lung pathobiology and cell cross talk using multi-omic 
 approaches expanding the horizons of therapeutic targets to slow\, halt\,
  reverse and regenerate progressively fibrosing lung tissue. Imaging and 
 AI are being harnessed more than ever to show therapeutic efficacy beyond
  lung function and clinical trials are being designed to be more effectiv
 e and swifter.\n\nThe 7th IPF Summit is the undisputed\, comprehensive\, 
 end-to-end\, 3-day conference for you and your team to grasp the latest r
 eadouts and take new insights back to your therapeutic development. Don't
  miss this opportunity to discuss the latest unpublished data and network
  with 180+ movers and shakers in the pulmonary fibrosis field.\n
DTEND:20230921T160000
DTSTAMP:20260307T144124Z
DTSTART:20230919T090000
LOCATION:Revere Hotel Boston Common\, 200\, Stuart Street\, Boston\, Suffo
 lk County\, 02116\,
SEQUENCE:0
SUMMARY:With Nintedanib and Pirfenidone set to lose their patents in the n
 ext 3-6 years\, Pliant Therapeutics moving into phase 2b\, readouts expec
 ted from F...
UID:3c375cb0-bd42-4eb0-8748-8c8ab069f6f1
END:VEVENT
END:VCALENDAR